From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服买家考虑的状态,转变为已获批准、指定、列入、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的重要部分可以在没有每次单独销售事件的情况下到来,并且管理层传达这种准入状态是新的,以至于它所带来的大部分业务量仍将在报告结果之后出现。 在记录中,管理层提到了与Johnson & Johnson创新药物签署的新协议,并推出了基于血液的生物标志物测试。但这是否意味着公司被纳入买方的系统?管理层提到“我们签署了一项新协议”,但并未明确说明这是否使公司成为默认选择或进入采购路径。此外,管理层提到“我们相信我们处于有利地位”,但未具体说明公司已被纳入任何系统。 关于报销或列入目录,管理层提到“我们预计医疗保险路径可能最初通过本地覆盖决定或未来可能成为国家覆盖决定”,但这是未来可能,并非已实现。管理层还提到“我们计划在接下来几个季度向FDA提交”,但这是未来计划。 因此,没有明确证据表明公司已获得此类准入状态。管理层描述的是销售关系、合作和未来计划,而非已实现的系统内准入。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.